Piper Sandler Initiates Coverage On Quest Diagnostics with Neutral Rating, Announces Price Target of $145
Portfolio Pulse from richadhand@benzinga.com
Piper Sandler analyst David Westenberg has initiated coverage on Quest Diagnostics (NYSE:DGX) with a Neutral rating and a price target of $145.
June 29, 2023 | 8:55 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Quest Diagnostics has been given a Neutral rating and a price target of $145 by Piper Sandler.
The initiation of coverage by Piper Sandler with a Neutral rating indicates that the firm does not expect significant price movement in the short term. The price target of $145 suggests that the firm believes the stock is fairly valued at this level. This could potentially limit the upside for the stock in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100